About us

About Cytovation

Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.

Who we are

Cytovation was founded in 2001 with strong ties to important scientific research groups at Haukeland University Hospital and the University of Bergen. The company is currently developing CyPep-1 for the treatment of benign skin tumours including cutaneous warts and is poised to begin toxicology studies in Q4 2016.

The company’s founders are well-renowned experts in their fields and the authors of an extensive number of scientific publications.

Targeting diseased skin cells

Cytovation’s proprietary product, CyPep-1, is a first-in-class peptide consisting of 27 amino acids with a unique mechanism that rapidly and selectively targets tumour cells due to altered electrochemical properties on their cell membranes not found on healthy cells. CyPep-1 is currently in pre-clinical development for the treatment of cutaneous warts caused by human papilloma virus (HPV) and has applications in other dermatological diseases.

What is CyPep-1?

Cytovation’s lead candidate CyPep-1 is a peptide consisting of 27 amino acids that selectively targets cutaneous warts and creates an immune response through the destruction of the cell membrane and release of antigens.

How it works

CyPep-1 rapidly and selectively targets diseased cells, due to a negative charge on their cell membranes not found on healthy cells, rapidly killing the wart cells by disrupting the cell membrane.  The destruction of the cell membrane and release of antigens from lysed cells has been shown to stimulate and recruit the immune system and could lead to long-term ‘protection.’

Why warts

There are currently no prescription medicines available for the treatment of cutaneous warts and over-the-counter products often do not permanently remove the wart. CyPep-1 is an effective potential prescription treatment for warts that can permanently eradicate the HPV virus.

Intellectual property

CyPep-1 has applications in other dermatological diseases and world-wide patent protection across the USA, Europe, Japan and China.

 

Board of Directors


Per Eystein Lønning, MD  PhD

Per Eystein Lønning, MD PhD

Chairman

Per Eystein Lønning, MD and PhD, is professor and senior consultant in oncology.

Per Eystein Lønning, MD and PhD, is professor and senior consultant in oncology.

Professor Rolf Bjerkvig, PhD

Professor Rolf Bjerkvig, PhD

Board member

Dr Bjerkvig is Professor in Cell Biology at the University of Bergen, Norway.

Dr Bjerkvig is Professor in Cell Biology at the University of Bergen, Norway.

Kristin Pundsnes

Kristin Pundsnes

Board Member

Kristin is currently Chief Financial Officer at Haukeland University Hospital, Bergen.

Kristin is currently Chief Financial Officer at Haukeland University Hospital, Bergen.

Leadership Team


Kjell-Inge Arnevig

Kjell-Inge Arnevig

Cheif Executive officer

Kjell-Inge Arnevig has more than 25 years’ experience in senior and executive positions.

Kjell-Inge Arnevig has more than 25 years’ experience in senior and executive positions.

Lars Prestegarden MD, PhD

Lars Prestegarden MD, PhD

Chief scientific officer

Dr Prestegarden is a co-founder of Cytovation and a board certified specialist in dermatology.

Dr Prestegarden is a co-founder of Cytovation and a board certified specialist in dermatology.